Ingenuity Systems Announces Immediate Availability Of The Ingenuity Pathways Knowledge Base


Mountain View, California, May 27, 2003 – Ingenuity Systems announced today the launch of the Ingenuity Pathways Knowledge Base, the world’s largest curated database of biological networks created from millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs, and diseases. Using this knowledge base, bioinformaticians are developing genome-scale computational solutions for understanding biological systems. This product is available for license to pharmaceutical and biotech companies. informatics groups focused on meeting the dual challenge of increasing R&D productivity while driving costs out of the drug discovery process.

The unparalleled breadth, depth and quality of the Ingenuity Pathways Knowledge Base sets a new standard for genome scale, structured biological information that is critical to computationally inferring new mechanisms of biological action. By helping researchers systematically analyze their experimental data in the context of biological pathways, the Ingenuity Pathways Knowledge Base provides value throughout the drug discovery process, from early stage target ID and validation, to later stage activities such as toxicology, pharmacogenomics, biomarker identification, and alternative indications of approved drugs.

Features include:

  • Integrated, broad coverage of systems biology including protein, gene, protein complex, cell, cellular component, tissue, organ, small molecule and disease interrelationships
  • Broad genome wide coverage of over 20,000 mammalian genes
  • Millions of pathway interactions extracted from literature
  • Semantic/linguistic consistency based on a comprehensive ontology with over 280,000 concepts, twenty-five times larger than other popular ontologies
  • Synonyms and homonyms maintain object identity and remove duplicate objects
  • Representation of biological context, including species specificity, localization, mutations, and experimental conditions
  • Systematic capture of well-established pathway relationships
  • Up to date with most recent literature

“We have been working with the Ingenuity technology for more than a year and our researchers are delighted with the results of the Ingenuity Pathways Knowledge Base,” stated Thomas P. Scarnecchia vice president, corporate informatics at Millennium Pharmaceuticals, Inc. “Now, we are increasingly deploying Ingenuity technology downstream in the drug discovery process where better understanding of pathways and biologic context has the potential to reduce the time and expense it takes to bring new therapeutics to market.”

The Ingenuity Pathways Knowledge Base is immediately available and includes quarterly updates, ‘getting started’ orientation, and ongoing consulting services to aid the informatics researcher who is creating custom-developed solutions tuned to specific R&D bottlenecks.

“The promise of systems biology is enticing, but until today, has been gated by the lack of availability of a high quality, genome-scale knowledge base such as ours,” stated Jake Leschly, president and chief executive officer of Ingenuity Systems. “Through use of the Pathways Knowledge Base our customers are gaining critical insights required to drive increased productivity and more attractive returns from their massive investment in genomic technologies over the past five years.”

Pricing for the Ingenuity Pathways Knowledge Base varies according to the customer.s intended use. Informatics professionals who are interested in evaluating the Ingenuity Pathways Knowledge Base product should contact Peter DiLaura at 650-967-7777, extension 299.

About Ingenuity Systems

Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.